Panel: Targeted Radiotherapy and the Impact on IO - a podcast by Pharma Talk Radio

What is the impact of targeted radiotherapy on the immune system?What are the implications for combination IO?Current approaches and future direction
Moderated by:

Michael Groaning, PhD, Global Medical Affairs Lead, Genitourinary, Amgen

Panelists:
Charles Glaus, PhD, Sr Director, Radiomics & Radiology Biomarkers, Bayer US-PharmaceuticalsJeff Legos, PhD, MBA, EVP, Global Head of Oncology & Hematology Development , NovartisMatthew Silva, PhD, CEO , InvicroOhad Ilovich, PhD, Senior Director, Translational Sciences, Curie Therapeutics
Learn more about the IO360° Summit at www.io360summit.com

Further episodes of PharmaTalkRadio

Further podcasts by Pharma Talk Radio

Website of Pharma Talk Radio